Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Michael CHEZ |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism / Michael CHEZ in Journal of Autism and Developmental Disorders, 50-5 (May 2020)
[article]
Titre : A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism Type de document : Texte imprimé et/ou numérique Auteurs : Michael CHEZ, Auteur ; Shawn KILE, Auteur ; Christopher LEPAGE, Auteur ; Carol PARISE, Auteur ; Bobbie BENABIDES, Auteur ; Andrea HANKINS, Auteur Article en page(s) : p.1532-1538 Langues : Anglais (eng) Mots-clés : Adults Aggression Autism spectrum disorder Dextromethorphan Irritability Placebo controlled crossover trial Quinidine Index. décimale : PER Périodiques Résumé : Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18-60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F1,10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism. En ligne : http://dx.doi.org/10.1007/s10803-018-3703-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=422
in Journal of Autism and Developmental Disorders > 50-5 (May 2020) . - p.1532-1538[article] A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism [Texte imprimé et/ou numérique] / Michael CHEZ, Auteur ; Shawn KILE, Auteur ; Christopher LEPAGE, Auteur ; Carol PARISE, Auteur ; Bobbie BENABIDES, Auteur ; Andrea HANKINS, Auteur . - p.1532-1538.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 50-5 (May 2020) . - p.1532-1538
Mots-clés : Adults Aggression Autism spectrum disorder Dextromethorphan Irritability Placebo controlled crossover trial Quinidine Index. décimale : PER Périodiques Résumé : Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18-60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F1,10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism. En ligne : http://dx.doi.org/10.1007/s10803-018-3703-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=422